Clinical Factors Associated With Bleeding In Ph-Negaitve MPN

Patients with Ph-negative myeloproliferative neoplasms (MPN) that include polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), share an increased risk of thrombotic and hemorrhagic complications. Risk factors for hemorrhagic complications are less defined compared to thromb...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2013-11, Vol.122 (21), p.3605-3605
Main Authors: Raza, Sania S., Zhou, Zheng, Stein, Brady L.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with Ph-negative myeloproliferative neoplasms (MPN) that include polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), share an increased risk of thrombotic and hemorrhagic complications. Risk factors for hemorrhagic complications are less defined compared to thrombosis, but acquired von Willebrand disease (aVWD) and extreme thrombocytosis have been implicated. To define whether aVWD, extreme thrombocytosis or treatment history associates with bleeding in Ph-negative MPN patients. The Northwestern University Electronic Data Warehouse identified MPN patients ≥18 years, seen between 2005-2013, with available testing for aVWD and/or extreme thrombocytosis, defined by a platelet count of > 800 x 109/L. Eligibility criteria also included availability of JAK2 status, complete blood count (CBC) results, clinical history and treatment history. aVWD was defined by vW antigen and/or ristocetin cofactor activity below the laboratory reference range for blood type (usually
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V122.21.3605.3605